PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Habringer, S.* ; Lapa, C.* ; Herhaus, P.* ; Schottelius, M.* ; Istvanffy, R.* ; Steiger, K.* ; Slotta-Huspenina, J.* ; Schirbel, A.* ; Hänscheid, H.* ; Kircher, S.* ; Buck, A.K.* ; Götze, K.* ; Vick, B. ; Jeremias, I. ; Schwaiger, M.* ; Peschel, C.* ; Oostendorp, R.* ; Wester, H.J.* ; Grigoleit, G.U.* ; Keller, U.*

Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics.

Theranostics 8, 369-383 (2018)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
C-X-C chemokine receptor 4 (CXCR4) is a transmembrane receptor with pivotal roles in cell homing and hematopoiesis. CXCR4 is also involved in survival, proliferation and dissemination of cancer, including acute lymphoblastic and myeloid leukemia (ALL, AML). Relapsed/refractory ALL and AML are frequently resistant to conventional therapy and novel highly active strategies are urgently needed to overcome resistance. Methods: We used patient-derived (PDX) and cell line-based xenograft mouse models of ALL and AML to evaluate the efficacy and toxicity of a CXCR4-targeted endoradiotherapy (ERT) theranostic approach. Results: The positron emission tomography (PET) tracer 68 Ga-Pentixafor enabled visualization of CXCR4 positive leukemic burden. In xenografts, CXCR4-directed ERT with 177 Lu-Pentixather distributed to leukemia harboring organs and resulted in efficient reduction of leukemia. Despite a substantial in vivo cross-fire effect to the leukemia microenvironment, mesenchymal stem cells (MSCs) subjected to ERT were viable and capable of supporting the growth and differentiation of non-targeted normal hematopoietic cells ex vivo. Finally, three patients with refractory AML after first allogeneic hematopoietic stem cell transplantation (alloSCT) underwent CXCR4-directed ERT resulting in leukemia clearance, second alloSCT, and successful hematopoietic engraftment. Conclusion: Targeting CXCR4 with ERT is feasible and provides a highly efficient means to reduce refractory acute leukemia for subsequent cellular therapies. Prospective clinical trials testing the incorporation of CXCR4 targeting into conditioning regimens for alloSCT are highly warranted.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
8.537
1.791
42
40
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Acute Leukemia ; C-x-c Chemokine Receptor 4 ; In Vivo Molecular Imaging ; Microenvironment ; Theranostics; Acute Lymphoblastic-leukemia; Acute Myeloid-leukemia; Stem-cell Transplantation; Bone-marrow; Multiple-myeloma; Neuroendocrine Tumors; Conditioning Regimen; Kinase Inhibitors; Cxcr4 Expression; In-vitro
Sprache englisch
Veröffentlichungsjahr 2018
HGF-Berichtsjahr 2018
e-ISSN 1838-7640
Zeitschrift Theranostics
Quellenangaben Band: 8, Heft: 2, Seiten: 369-383 Artikelnummer: , Supplement: ,
Verlag Ivyspring
Verlagsort Lake Haven
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Apoptosis in Hematopoietic Stem Cells (AHS)
POF Topic(s) 30204 - Cell Programming and Repair
Forschungsfeld(er) Stem Cell and Neuroscience
PSP-Element(e) G-506600-001
DOI 10.7150/thno.21397
WOS ID WOS:000417098700006
Scopus ID 85035081863
PubMed ID 29290814
Erfassungsdatum 2018-01-23
[➜Korrektur melden]